Please login to the form below

Not currently logged in
Email:
Password:

bococizumab

This page shows the latest bococizumab news and features for those working in and with pharma, biotech and healthcare.

Amgen wins block on sales of Sanofi/Regeneron's Praluent

Amgen wins block on sales of Sanofi/Regeneron's Praluent

A potential third entrant - Pfizer's bococizumab - was dropped from development last year.

Latest news

  • Amgen's Repatha unclogs blocked arteries, says study Amgen's Repatha unclogs blocked arteries, says study

    The difficulties experienced by the first two PCSK9 inhibitors in the market played a role in Pfizer deciding to drop its own candidate bococizumab, which was set to become the third

  • Pfizer dropping bococizumab casts shadow over PCSK9 class Pfizer dropping bococizumab casts shadow over PCSK9 class

    Pfizer has decided it will no longer try to bring its cholesterol-lowering antibody bococizumab to market, blaming the decision in part on payer resistance in the US. ... Payer resistance is not the only reason for the decision, however, as Read also

  • Pfizer's PCSK9 inhibitor clears another phase III trial Pfizer's PCSK9 inhibitor clears another phase III trial

    Pfizer has reported positive phase III trial results with its cholesterol-lowering candidate bococizumab, setting up a possible regulatory filing in the coming months. ... An earlier trial called SPIRE-SI met its objective of showing that bococizumab was

  • Amgen starts shipping Corlaner in US Amgen starts shipping Corlaner in US

    Repatha and other PCSK9 inhibitors such as Sanofi/Regeneron's alirocumab and Pfizer's bococizumab are considered future blockbusters thanks to their ability to help more patients meet cholesterol targets.

  • Monthly dosing effective for Sanofi's alirocumab Monthly dosing effective for Sanofi's alirocumab

    A third PCSK9 inhibitor - Pfizer's bococizumab (RN316) - has also reported results from phase III trials but is expected to lag a little behind the leaders in terms of market share.

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...
Digital therapeutics and their impact on society
Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic?...

Infographics